Literature DB >> 21909651

Comparison of the Etest and a rapid flow cytometry-based method with the reference CLSI broth microdilution protocol M27-A3 for the echinocandin susceptibility testing of Candida spp.

L A Vale-Silva1, P Pinto, V Lopes, H Ramos, E Pinto.   

Abstract

Reference broth microdilution protocols for the antifungal susceptibility testing (AST) of yeasts are available, but routine AST relies more on simpler alternatives. In this work, the Etest and a novel flow cytometry (FC) method were compared to the Clinical Laboratory Standards Institute (CLSI) protocol M27-A3. Caspofungin and anidulafungin were tested against 60 clinical isolates of Candida glabrata, C. krusei, and C. parapsilosis. There were two intermediate susceptibility results and 19 out of 20 tested C. krusei strains were categorized as resistant to caspofungin (minimum inhibitory concentration [MIC] of 1.0 mg/L). There was a generally excellent essential agreement with the reference method, only interrupted by Etest results for the anidulafungin susceptibility of C. glabrata (80%) and the FC method's results for caspofungin with C. krusei (40%). Categorical agreements were excellent, with the notable exception of the caspofungin-resistant C. krusei, with 19 very major errors for the FC method and 19 minor errors plus one very major error for the Etest (5% and 0% categorical agreements, respectively). Two additional minor errors were registered for the FC method when testing C. parapsilosis with anidulafungin and caspofungin. Overall, these data come to question the suitability of recently approved clinical breakpoints in the case of C. krusei. Further studies including fks mutants are now required.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21909651     DOI: 10.1007/s10096-011-1390-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  25 in total

Review 1.  Antifungal susceptibility testing by flow cytometry: is it the future?

Authors:  Luís André Vale-Silva; Vladimír Buchta
Journal:  Mycoses       Date:  2006-07       Impact factor: 4.377

2.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

Review 3.  The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro.

Authors:  Manuel Cuenca-Estrella; Juan Luis Rodriguez-Tudela
Journal:  Expert Rev Anti Infect Ther       Date:  2010-03       Impact factor: 5.091

4.  Comparison of two probes for testing susceptibilities of pathogenic yeasts to voriconazole, itraconazole, and caspofungin by flow cytometry.

Authors:  Cidália Pina-Vaz; Sofia Costa-de-Oliveira; Acácio G Rodrigues; Ana Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

5.  Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.

Authors:  George R Thompson; Nathan P Wiederhold; Ana C Vallor; Nyria C Villareal; James S Lewis; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

Review 6.  The echinocandins: three useful choices or three too many?

Authors:  A M Bal
Journal:  Int J Antimicrob Agents       Date:  2009-11-25       Impact factor: 5.283

7.  Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; R N Jones; J Turnidge; D J Diekema
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

8.  Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection.

Authors:  Nikolaos V Sipsas; Russell E Lewis; Jeffrey Tarrand; Ray Hachem; Kenneth V Rolston; Issam I Raad; Dimitrios P Kontoyiannis
Journal:  Cancer       Date:  2009-10-15       Impact factor: 6.860

9.  A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.

Authors:  Guillermo Garcia-Effron; Santosh K Katiyar; Steven Park; Thomas D Edlind; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

Review 10.  In vitro susceptibility testing in fungi: a global perspective on a variety of methods.

Authors:  Cornelia Lass-Flörl; Susanne Perkhofer; Astrid Mayr
Journal:  Mycoses       Date:  2010-01       Impact factor: 4.377

View more
  3 in total

Review 1.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

2.  Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints.

Authors:  Maiken Cavling Arendrup; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

Review 3.  Antifungal susceptibility testing: current role from the clinical laboratory perspective.

Authors:  Brunella Posteraro; Riccardo Torelli; Elena De Carolis; Patrizia Posteraro; Maurizio Sanguinetti
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-04-07       Impact factor: 2.576

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.